Abgenix Announces Initiation of a Phase 2 Clinical Trial of ABX-EGF
in Combination With Chemotherapy in Patients With Colorectal Cancer
ABX-EGF is a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), a receptor identified in many solid tumor types. The multi-center, open-label Phase 2 study will enroll up to 84 patients. Patients will receive weekly intravenous infusions of 2.5 mg/kg of ABX-EGF in combination with standard doses of irinotecan, leucovorin, and 5-fluorouracil over a 6-week treatment cycle, for up to eight cycles.
"For patients with colorectal cancer, we are evaluating ABX-EGF as a monotherapy, as well as in combination with standard chemotherapy in two separate Phase 2 studies," stated R. Scott Greer, chairman and chief executive officer of Abgenix. "We are pleased with the progress the joint Abgenix/Immunex team has made in advancing development of our lead antibody candidate for cancer."
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.